|
1
|
Siegel R, DeSantis C, Virgo K, et al:
Cancer treatment and survivorship statistics, 2012. CA Cancer J
Clin. 62:220–241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lucas AS, O’Neil BH and Goldberg RM: A
decade of advances in cytotoxic chemotherapy for metastatic
colorectal cancer. Clin Colorectal Cancer. 10:238–244. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dallas NA, Xia L, Fan F, et al:
Chemoresistant colorectal cancer cells, the cancer stem cell
phenotype, and increased sensitivity to insulin-like growth
factor-I receptor inhibition. Cancer Res. 69:1951–1957. 2009.
View Article : Google Scholar
|
|
4
|
Aschele C, Bergamo F and Lonardi S:
Chemotherapy for operable and advanced colorectal cancer. Cancer
Treat Rev. 35:509–516. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zou K, Ju J and Xie H: Pretreatment with
insulin enhances anticancer functions of 5-fluorouracil in human
esophageal and colonic cancer cells. Acta Pharmacol Sin.
28:721–730. 2007. View Article : Google Scholar
|
|
6
|
Graham J, Muhsin M and Kirkpatrick P:
Oxaliplatin. Nat Rev Drug Discov. 3:11–12. 2004. View Article : Google Scholar
|
|
7
|
Armand JP, Ducreux M, Mahjoubi M, et al:
CPT-11 (Irinotecan) in the treatment of colorectal cancer. Eur J
Cancer. 31A:1283–1287. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Calle EE, Rodriguez C, Walker-Thurmond K
and Thun MJ: Overweight, obesity, and mortality from cancer in a
prospectively studied cohort of U.S. adults. N Engl J Med.
348:1625–1638. 2003. View Article : Google Scholar
|
|
9
|
Moghaddam AA, Woodward M and Huxley R:
Obesity and risk of colorectal cacner: a meta-analysis of 31
studies with 70,000 events. Cancer Epidemiol Biomarkers Prev.
16:2533–2547. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Renehan AG, Tyson M, Egger M, Heller RF
and Zwahlen M: Body-mass index and incidence of cancer: a
systematic review and meta-analysis of prospective observational
studies. Lancet. 371:569–578. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Campbell PT, Newton CC, Dehal AN, Jacobs
EJ, Patel AV and Gapstur SM: Impact of body mass index on survival
after colorectal cancer diagnosis: the Cancer Prevention Study-II
Nutrition Cohort. J Clin Oncol. 30:42–52. 2012. View Article : Google Scholar
|
|
12
|
Simkens LH, Koopman M, Mol L, et al:
Influence of body mass index on outcome in advanced colorectal
cancer patients receiving chemotherapy with or without targeted
therapy. Eur J Cancer. 47:2560–2567. 2011. View Article : Google Scholar
|
|
13
|
Meyerhardt JA, Niedzwiecki D, Hollis D, et
al: Impact of body mass index and weight change after treatment on
cancer recurrence and survival in patients with stage III colon
cancer: findings from Cancer and Leukemia Group B 89803. J Clin
Oncol. 26:4109–4115. 2008. View Article : Google Scholar
|
|
14
|
Griggs JJ and Sabel MS: Obesity and cancer
treatment: weighing the evidence. J Clin Oncol. 26:4060–4062. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Litton JK, Gonzalez-Angulo AM, Warneke CL,
et al: Relationship between obesity and pathologic response to
neoadjuvant chemotherapy among women with operable breast cancer. J
Clin Oncol. 26:4072–4077. 2008. View Article : Google Scholar
|
|
16
|
Pollak M: Insulin and insulin-like growth
factor signalling in neoplasia. Nat Rev Cancer. 8:915–928. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ahmed RL, Thomas W and Schmitz KH:
Interactions between insulin, body fat, and insulin-like growth
factor axis proteins. Cancer Epidemiol Biomarkers Prev. 16:593–597.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Biddinger SB and Kahn CR: From mice to
men: insights into the insulin resistance syndromes. Annu Rev
Physiol. 68:123–158. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Renehan AG, Frystyk J and Flyvbjerg A:
Obesity and cancer risk: the role of the insulin-IGF axis. Trends
Endocrinol Metab. 17:328–336. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen J, Katsifis A, Hu C and Huang XF:
Insulin decreases therapeutic efficacy in colon cancer cell line
HT29 via the activation of the PI3K/Akt pathway. Curr Drug Discov
Technol. 8:119–125. 2011. View Article : Google Scholar
|
|
21
|
Adachi Y, Lee CT, Coffee K, et al: Effects
of genetic blockade of the insulin-like growth factor receptor in
human colon cancer cell lines. Gastroenterology. 123:1191–1204.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gooch JL, Van Den Berg CL and Yee D:
Insulin-like growth factor (IGF)-1 rescues breast cancer cells from
chemotherapy-induced cell death - proliferative and anti-apoptotic
effects. Breast Cancer Res Treat. 56:1–10. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Perer ES, Madan AK, Shurin A, et al:
Insulin-like growth factor I receptor antagonism augments response
to chemoradiation therapy in colon cancer cells. J Surg Res.
94:1–5. 2000. View Article : Google Scholar
|
|
24
|
Roberts DL, Williams KJ, Cowen RL, et al:
Contribution of HIF-1 and drug penetrance to oxaliplatin resistance
in hypoxic colorectal cancer cells. Br J Cancer. 101:1290–1297.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mole DR and Ratcliffe PJ: Cellular oxygen
sensing in health and disease. Pediatr Nephrol. 23:681–694. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fukuda R, Hirota K, Fan F, Jung YD, Ellis
LM and Semenza GL: Insulin-like growth factor 1 induces
hypoxia-inducible factor 1-mediated vascular endothelial growth
factor expression, which is dependent on MAP kinase and
phosphatidylinositol 3-kinase signaling in colon cancer cells. J
Biol Chem. 277:38205–38211. 2002. View Article : Google Scholar
|
|
27
|
Doronzo G, Russo I, Mattiello L, Riganti
C, Anfossi G and Trovati M: Insulin activates hypoxia-inducible
factor-1alpha in human and rat vascular smooth muscle cells via
phosphatidylinositol-3 kinase and mitogen-activated protein kinase
pathways: impairment in insulin resistance owing to defects in
insulin signalling. Diabetologia. 49:1049–1063. 2006. View Article : Google Scholar
|
|
28
|
Ades EW, Candal FJ, Swerlick RA, George
VG, Summers S, Bosse DC and Lawley TJ: HMEC-1: establishment of an
immortalized human microvascular endothelial cell line. J Invest
Dermatol. 99:683–690. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mosmann T: Rapid colorimetric assay for
cellular growth and survival: application to proliferation and
cytotoxicity assays. J Immunol Methods. 65:55–63. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang P, Henning SM and Heber D:
Limitations of MTT and MTS-based assays for measurement of
antiproliferative activity of green tea polyphenols. PLoS One.
5:e102022010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dachs GU, Steele AJ, Coralli C, et al:
Anti-vascular agent Combretastatin A-4-P modulates hypoxia
inducible factor-1 and gene expression. BMC Cancer. 6:2802006.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
American Diabetes Association. Diagnosis
and classification of diabetes mellitus. Diabetes Care. 35(Suppl
1): S64–S71. 2012. View Article : Google Scholar
|
|
33
|
Bartrons R and Caro J: Hypoxia, glucose
metabolism and the Warburg’s effect. J Bioenerg Biomembr.
39:223–229. 2007.
|
|
34
|
Costa A, Rios M, Casamitjana R, Gomis R
and Conget I: High prevalence of abnormal glucose tolerance and
metabolic disturbances in first degree relatives of NIDDM patients.
A study in Catalonia, a mediterranean community. Diabetes Res Clin
Pract. 41:191–196. 1998. View Article : Google Scholar
|
|
35
|
Kajantie E, Fall CH, Seppälä M, et al:
Serum insulin-like growth factor (IGF)-I and IGF-binding protein-1
in elderly people: relationships with cardiovascular risk factors,
body composition, size at birth, and childhood growth. J Clin
Endocrinol Metab. 88:1059–1065. 2003. View Article : Google Scholar
|
|
36
|
Lahm H, Amstad P, Wyniger J, Yilmaz A,
Fischer JR, Schreyer M and Givel JC: Blockade of the insulin-like
growth-factor-I receptor inhibits growth of human colorectal cancer
cells: evidence of a functional IGF-II-mediated autocrine loop. Int
J Cancer. 58:452–459. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bocci G, Danesi R, Di Paolo AD, et al:
Comparative pharmacokinetic analysis of 5-fluorouracil and its
major metabolite 5-fluoro-5,6-dihydrouracil after conventional and
reduced test dose in cancer patients. Clin Cancer Res. 6:3032–3037.
2000.
|
|
38
|
Morrison JG, White P, McDougall S, et al:
Validation of a highly sensitive ICP-MS method for the
determination of platinum in biofluids: application to clinical
pharmacokinetic studies with oxaliplatin. J Pharm Biomed Anal.
24:1–10. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Casale F, Canaparo R, Serpe L, Muntoni E,
Pepa CD, Costa M, Mairone L, Zara GP, Fornari G and Eandi M: Plasma
concentrations of 5-fluorouracil and its metabolites in colon
cancer patients. Pharmacol Res. 50:173–179. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kjellström J, Kjellén E and Johnsson A: In
vitro radiosensitization by oxaliplatin and 5-fluorouracil in a
human colon cancer cell line. Acta Oncol. 44:687–693.
2005.PubMed/NCBI
|
|
41
|
Takimoto CH, Morrison G, Harold N, et al:
Phase I and pharmacologic study of irinotecan administered as a
96-hour infusion weekly to adult cancer patients. J Clin Oncol.
18:659–667. 2000.
|
|
42
|
Tobin PJ, Beale P, Noney L, et al: A pilot
study on the safety of combining chrysin, a non-absorbable inducer
of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal
cancer. Cancer Chemother Pharmacol. 57:309–316. 2006. View Article : Google Scholar
|
|
43
|
Hunter RJ, Navo MA, Thaker PH, Bodurka DC,
Wolf JK and Smith JA: Dosing chemotherapy in obese patients: actual
versus assigned body surface area (BSA). Cancer Treat Rev.
35:69–78. 2009. View Article : Google Scholar
|
|
44
|
Chambers P, Daniels SH, Thompson LC and
Stephens RJ: Chemotherapy dose reductions in obese patients with
colorectal cancer. Ann Oncol. 23:748–753. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ayre SG, Garcia y Bellon DP and Garcia DP
Jr: Insulin, chemotherapy, and the mechanisms of malignancy: the
design and the demise of cancer. Med Hypotheses. 55:330–334. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Damyanov C, Radoslavova M, Gavrilov V and
Stoeva D: Low dose chemotherapy in combination with insulin for the
treatment of advanced metastatic tumors. Preliminary experience. J
BUON. 14:711–715. 2009.PubMed/NCBI
|
|
47
|
Min Y, Adachi Y, Yamamoto H, et al:
Insulin-like growth factor I receptor blockade enhances
chemotherapy and radiation responses and inhibits tumour growth in
human gastric cancer xenografts. Gut. 54:591–600. 2005. View Article : Google Scholar
|
|
48
|
Warshamana-Greene GS, Litz J, Buchdunger
E, Garcia-Echeverria C, Hofmann F and Krystal GW: The insulin-like
growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes
small cell lung cancer cell lines to the effects of chemotherapy.
Clin Cancer Res. 11:1563–1571. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Desbois-Mouthon C, Cadoret A, Blivet-Van
Eggelpoël MJ, et al: Insulin-mediated cell proliferation and
survival involve inhibition of c-Jun N-terminal kinases through a
phosphatidylinositol 3-kinase- and mitogen-activated protein kinase
phosphatase-1-dependent pathway. Endocrinology. 141:922–931.
2000.
|
|
50
|
Hopkins A, Crowe PJ and Yang JL: Effect of
type 1 insulin-like growth factor receptor targeted therapy on
chemotherapy in human cancer and the mechanisms involved. J Cancer
Res Clin Oncol. 136:639–650. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Sung MK, Yeon JY, Park SY, Park JH and
Choi MS: Obesity-induced metabolic stresses in breast and colon
cancer. Ann NY Acad Sci. 1229:61–68. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Scharte M, Jurk K, Kehrel B, Zarbock A,
Van Aken H and Singbartl K: IL-4 enhances hypoxia induced
HIF-1alpha protein levels in human transformed intestinal cells.
FEBS Lett. 580:6399–6404. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Ikediobi ON, Davies H, Bignell G, et al:
Mutation analysis of 24 known cancer genes in the NCI-60 cell line
set. Mol Cancer Ther. 5:2606–2612. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Spitzner M, Emons G, Kramer F, et al: A
gene expression signature for chemoradiosensitivity of colorectal
cancer cells. Int J Radiat Oncol Biol Phys. 78:1184–1192. 2010.
View Article : Google Scholar : PubMed/NCBI
|
